ClinicalTrials.gg
RecruitingNCT07597980Updated Oct 15, 2026

Lifestyle Intervention to Improve Muscle Function in Older Adults

An interventional study of Structured nutrition plan and Typical or usual diet in Body Composition, Physical Function and Energy Balance, sponsored by Pennington Biomedical Research Center. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 15, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The goal of this randomized controlled two-arm trial is to determine the effect of a diet and exercise intervention for 12 weeks on body composition, muscle function, and energy balance in 80 adults aged 50 years and over with obesity and insulin resistance. The main questions the trial aims to answer are: Will 12 weeks of a structured nutrition plan + exercise reduce fat mass, improve muscle function, and increase energy deficit compared to the usual diet + exercise. The hypothesis is that 12 weeks of a structured nutrition plan + exercise will reduce fat mass, improve muscle function, and produce greater energy deficit than the usual diet + exercise. Participants will be provided with all meals for 12 weeks and will exercise at the Center under supervision three times each week. Pre and post-intervention, body composition, physical function, and energy deficit will be measured.

Read the detailed description

In the United States nearly one third of adults over 60 years of age have sarcopenic obesity which encompasses the combined effect of muscle impairment and obesity. A strategy that addresses the combined effect of muscle impairment and obesity while modulating muscle mass and composition is an unanswered challenge. This 12-week study will evaluate the effects of a structured nutrition plan combined with an exercise program on body fat and muscle mass, lower-extremity function (Short Physical Performance Battery), muscle strength (handgrip and knee strength), and daily caloric intake. The study will enroll adults aged 50 years and older with obesity (body mass index ≥ 30 kg/m²) and insulin resistance as indicated by a homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 3. Subjects will be randomly allocated to receive the structured nutrition plan and exercise intervention or to their usual diet and exercise in equal numbers (40 per group). The study will enrich our understanding of the physiological adaptations necessary for effective lifestyle interventions to improve muscle function.

02

Conditions studied

  • Body Composition
  • Physical Function
  • Energy Balance

Keywords

  • Fat mass
  • muscle mass
  • physical function
  • energy deficit
03

In context

Lead sponsor

Pennington Biomedical Research Center is the lead sponsor of 284 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 50 years.
  2. (BMI) ≥ 30 kg/m2.
  3. Homeostatic model assessment of insulin resistance ≥ 3.
  4. (MMSE) > 25.
  5. Geriatric Depression Scale-15 (GDS-15) \< 9.
  6. Sedentary (less than 90 minutes/week of moderate to vigorous activity).
  7. Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of cancer (received within five years) or diabetes (type 1 and 2), or significant musculoskeletal, or cardiovascular, or hepatic, or renal, disease or dysfunction.
  2. gastrointestinal malabsorption syndromes such as chronic diarrhea, celiac disease, or clinically significant abnormal laboratory markers.
  3. Fluctuation in body weight > 3 kg in the preceding two months
  4. Condition that impedes testing of the study hypothesis or makes it unsafe to exercise or consume the study foods.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Structured nutrition plan + exercise

    Intervention: Participants receive a structured nutrition plan, and exercise under supervision.

    Behavioral: Structured nutrition plan · Behavioral: Supervised Exercise

  • Active comparator
    Typical or usual diet + exercise

    Participants receive a typical or usual diet, and exercise under supervision

    Behavioral: Typical or usual diet · Behavioral: Supervised Exercise

Interventions

  • BehavioralStructured nutrition plan

    Participants will receive a structured nutrition plan.

  • BehavioralTypical or usual diet

    Participants will receive a diet representing the usual diet in this population.

  • BehavioralSupervised Exercise

    Participants will complete aerobic and resistance training under supervision three times per week.

06

What researchers measure

Primary outcomes

  1. Fat mass

    Fat mass measured by dual X-ray absorptiometry

    Time frame: Change from baseline to 12 weeks

Secondary outcomes

  1. Skeletal muscle mass

    Skeletal muscle mass will be measured by the creatine methyl D-3 dilution method

    Time frame: Change in from baseline to 12 weeks

  2. Short physical performance battery

    A test of physical function

    Time frame: Change from baseline to 12 weeks

  3. Hand-grip strength

    Hand grip strength will be measured using a hand dynamometer

    Time frame: Change from baseline to 12 weeks

  4. Knee strength

    Knee strength will be measured quantified using Biodex dynamometry

    Time frame: Change from baseline to12 weeks

  5. Energy stores

    Change in energy stores/day (kcal) determined from measures of body composition using the energy balance method

    Time frame: 12 weeks

  6. Hormonal regulation of energy balance

    Blood concentrations of glucagon-like peptide 1

    Time frame: Change from baseline to 12 weeks

  7. Hormonal regulation of energy balance

    Blood concentrations of gastric inhibitory peptide

    Time frame: Change from baseline to 12 weeks

  8. Hormonal regulation of energy balance

    Blood concentrations of cortisol

    Time frame: Change from baseline to 12 weeks

  9. Hormonal regulation of energy balance

    Blood concentrations of leptin

    Time frame: Change from baseline to 12 weeks

  10. Cardiorespiratory fitness

    VO2max

    Time frame: Change in VO2max from baseline to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — At this time, we do not have plans to share IPD. We may consider it after the study results have been publicly disseminated

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Jun 2030, 47 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2030 → Jun 2030, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 20, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Jun 2030was Dec 2030
CompletionEst.
Dec 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2030→Jun 2030
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Dec 2030→Jun 2030

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597980
Responsible party
Candida Rebello (Assistant Professor, Pennington Biomedical Research Center) — Principal investigator
First posted
May 20, 2026
Start date
Jul 20, 2026
Primary completion
Jun 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Candida J Rebello, PhD, RD
Contact
Candida.Rebello@pbrc.edu
12257633159
Reilly Roberts A Project Manager, MS
Contact
candidajoan@hotmail.com
225-763-2854
Candida J Rebello, PhD, RD
principal investigator · Pennington Biomedical Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion